ClinicalTrials.gg
TerminatedNCT03386929SPRINGUpdated Dec 18, 2023Results posted

Survival Prolongation by Rationale Innovative Genomics

A Phase 1/2 interventional study of Avelumab and Axitinib in Non-small Cell Lung Cancer Metastatic and Non-small Cell Lung Cancer Stage IIIB, sponsored by Worldwide Innovative Network Association. Terminated at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-18.

Sponsored by Worldwide Innovative Network Association · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The SPRING trial had to be early terminated at the end of the Phase 1 portion of the study due to the absence of funding necessary for the performance of the Phase 2.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing avelumab in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, 1 of them phase 3. avelumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
13th of 15
15 · median 67
Started
2017
with 4 others
Phase 1/2
5 of 15
1 open now
Registered
9th of 15
by date
Lead sponsor
1 of 15
Worldwide Innovative Network Association

Among the 15 studies testing avelumab in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by enrollment, is one of 5 that started in 2017, is one of 5 in phase 1/2, and was the 9th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 15 studies testing avelumab in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About avelumab

avelumab: first FDA approval 2017 (BAVENCIO), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing avelumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Patients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic Lymphoma Kinase (ALK) translocation, ROS1 mutation if available or MET exon 14 skipping mutation if available) will receive a tri-therapy associating avelumab, axitinib and palbociclib.

Read the detailed description

During the Phase 1 (approximately 30 patients), the tri-therapy will be tested at different doses following a specific dose-escalation scheme (3 + 3 model) in order to establish the safety and identify the Maximum Tolerated Dose (MTD) and recommended dose for the Phase 2 (RP2D). The phase 2 will confirm the safety and will assess the clinical utility of the tri-therapy approach in the treatment of advanced/metastatic NSCLC (100 patients). The study will also explore the clinical utility of the Simplified Interventional Mapping System (SIMS), a new tool/algorithm enabling matching of NSCLC patients with combination therapy. For this purpose tumor/metastasis and matched normal tissue biopsies will be requested in order to obtain sequencing and expression profiles.

03

Conditions studied

  • Non-small Cell Lung Cancer Metastatic
  • Non-small Cell Lung Cancer Stage IIIB

Keywords

  • NSCLC
  • tri-therapy
  • avelumab
  • axitinib
  • palbociclib
  • dual matched normal and tumor biopsies
  • SIMS algorithm
  • Sequencing
  • Gene expression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

ELIGIBILITY CRITERIA

  • Age: Men and women aged >18 years,
  • Signed written ,
  • Any histologic type of locally advanced or NSCLC,
  • of ≥ 12 weeks,
  • Measurable or evaluable (cytologically or radiologically detectable disease such as ascites, peritoneal deposits, or lesions which do not fulfill 1.1 criteria for ) lesions according to RECIST 1.1 criteria for phase 1 portion. For phase 2, all patients must have RECIST 1.1 measurable disease,
  • Physiologic function:

    • Hematologic: (ANC) ≥ 1.5 × 109/L, count ≥ 100 × 109/L, and ≥ 9 g/dL (may have been transfused),
    • Hepatic: Total level ≤ 1.5 × the (ULN) range and (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 × ULN,
    • Renal: Estimated ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method).
  • Pregnancy and :

    • Pregnancy test: Negative serum or urine pregnancy test at screening for women of .
    • Contraception: Highly effective contraception for both male and female subjects throughout the study and for at least 90 days after last treatment administration if the risk of conception exists.
  • Ability to comply with protocol requirements,
  • Willingness to consent and ability to undergo a trucut to obtain a fresh metastasis or primary tumor biopsy, and to undergo bronchoscopy to obtain a biopsy from normal bronchial mucosa,
  • No serious or medically uncontrolled concomitant conditions that are likely to make the patient unfit for SPRING combination therapy, as per investigator assessment,
  • performance status of 0 to 1.

EXCLUSION CRITERIA

  • Patients with documented oncogenic aberrations at enrollment: EGFR, ALK, ROS1 when available, MET exon 14 skipping when available. For squamous undifferentiated cell carcinoma, documentation of these aberrations is not mandatory. Note: For Phase 1 portion, all patients with adenocarcinoma histology must have documentation of results for druggable oncogenic aberrations (EGFR mutations, ALK rearrangements, and ROS1 when available) prior to enrollment on the study.
  • For Phase 1 portion, >2 in the metastatic setting.
  • For the dose escalation phase of the study or until the MTD for the combination regimen has been determined, patients with moderate hepatic impairment defined as AST, ALT, alkaline phosphatase (ALP) >5 times ULN, which would be grade 3 or higher. However, patients with liver metastases with AST/ALT ≤ 5 x ULN can be included in the study.
  • For Phase 2 portion, any prior therapy in the metastatic setting.

Clinical criteria for phase 1 and phase 2 studies:

  • Patients with treated are eligible as are patients with new, active untreated brain metastasis.
  • Participants with a history of myocardial infarction within the last 2 years or with significant cardiac arrhythmias uncontrolled by medication or pacemaker,
  • Participants with any history of interstitial lung disease,
  • Prior toxicities from anticancer agents or radiotherapy which have not regressed to Grade ≤ 1 severity ( version 4.03) apart from peripheral neuropathy and alopecia,
  • History of any second in the last two years; patients with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible. Patients with a history of other malignancies are eligible if they have been continuously disease-free for at least two years,
  • condition requiring medical intervention,
  • Uncontrolled concomitant illness, active infection requiring i.v. antibiotics,
  • Patients who have had a thromboembolic event within six months are excluded, as are patients on anticoagulants, except for low dose aspirin (\<100 mg/day) and low doses of anticoagulants meant to keep line access open;
  • Patients with Grade 3 or 4 (serious) gastrointestinal bleeding within the last six months are excluded.
  • Prior > G3 hemoptysis, major blood vessel involvement (specifically including aorta, superior and inferior vena cave, main pulmonary arteries and veins, subclavian arteries and veins and other large blood vessels that in the investigator's opinion places the patients at high risk for major bleeding), and/or central cavitations,
  • Known or suspected drug to any drug used in the combination,
  • Difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the oral drugs,
  • Any condition (e.g., known or suspected poor compliance, psychological instability, geographical location, etc.) that, in the judgment of the investigator may affect the patient's ability to sign the informed consent and undergo study procedures,
  • Taking another experimental drug within 28 days prior to day 1 of the protocol medications in this study,
  • Pregnant or breast-feeding women,
  • Both male and female patients of must agree to use highly effective contraception, during the study and for 3 months following the last dose of study drug,
  • Patients currently taking strong inducers and inhibitors,
  • Patients currently taking proton pump inhibitors due to their impact on the disposition of palbociclib during the phase 1.
  • Patients taking other anticancer agents with the exception of denosumab or equivalent medication for bone metastases.
  • A time period of at least three weeks (including radiotherapy) or five drug half-lives, whichever is shorter must have elapsed from last non- therapy before first day of treatment on this study,
  • A time period of at least 10 days must have elapsed from last palliative radiotherapy before the first day of treatment on this study,
  • Specific exclusion criteria for administration of avelumab, in combination:

    • IMMUNOSUPRESSANTS: Current use of medication, EXCEPT for the following: a. intranasal, inhaled, topical , or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
    • AUTOIMMUNE DISEASE: Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
    • ORGAN TRANSPLANTATION: Prior organ transplantation including allogenic stem-cell transplantation.
    • INFECTIONS: Active infection requiring IV (Intra venous) therapy.
    • /AIDS: Known history of testing positive for HIV or known acquired immunodeficiency syndrome.
    • HEPATITIS: virus (HBV) or virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).
    • VACCINATION: Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.
    • HYPERSENSITIVITY TO STUDY DRUG: Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade ≥ 3).
    • CARDIOVASCULAR DISEASE: Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ Classification Class II), or serious cardiac arrhythmia inadequately controlled by medication.
    • OTHER PERSISTING TOXICITIES: Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.
    • Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Avelumab, Axitinib, Palbociclib

    For the Phase 1: Avelumab is administered intravenously (IV) on Day 1 and Day 15 of a 28 day cycle in combination with axitinib po bid (every day of a 28 day cycle) and palbociclib po (on days 8-28 of a 28 day cycle). For the Phase 2: Avelumab, axitinib and palbociclib are administered at the recommended phase 2 dose (RP2D) as determined during the phase 1 part of the study.

    Drug: Avelumab · Drug: Axitinib · Drug: Palbociclib

Interventions

  • A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.

  • A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.

    Also known as: Inlyta

  • A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.

    Also known as: Ibrance

06

What researchers measure

Primary outcomes

  1. Incidence of the Tested 3-Drug Combination Therapy-Emergent Adverse Events and Serious Adverse Events

    The occurrence of adverse events and serious adverse events reported from the signing of an informed consent through 90 days after the last administration of the treatment will be summarized for all subjects who received at least one dose of the study treatment (safety population) and will be evaluated based on NCI CTCAE v4.03: June 14, 2010.

    Time frame: From informed consent signature through 90 days after administration of the treatment (last dose)

  2. Response Rate (RR)

    Response rate is defined as the proportion of participants with reduction in tumor burden of a predefined amount based on RECIST 1.1 evaluation

    Time frame: Baseline up to approximately 24 months

  3. Duration of the Response

    Duration of Response (DR) is defined for patients with confirmed objective response (Complete Response \[CR\] or Partial Response \[PR\]) as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.

    Time frame: Baseline up to approximately 24 months

  4. Progression-Free Survival (PFS)

    Progression Free Survival (PFS) is defined as the time from the first dose of study treatment to the date of disease progression by RECIST 1.1 or death due to any cause, whichever occurs first.

    Time frame: Baseline up to approximately 24 months

  5. Overall Survival (OS)

    OS is defined as the time from the first dose of study treatment to the date of death due to any cause.

    Time frame: Baseline up to approximately 24 months

  6. SIMS Algorithm to Predict Clinical Outcome

    The proportion of participants whose SIMS analysis matches the treatment combination, will be correlated retrospectively to clinical outcome.

    Time frame: 4 years

Secondary outcomes

  1. Incidence of Treatment-related and or Biopsy-related Serious Adverse Events

    The occurrence of treatment-related and or biopsy-related serious adverse events as assessed by NCI CTCAE v4.03 will be summarized for all study subjects.

    Time frame: 4 years

  2. Genomic and Transcriptomic Profile

    Genomic (DNA) and transcriptomic (RNA) aberrations (mutations, translocations, rearrangements and changes in expression level) identified in the study population (Non-Small Cell Lung) will be described.

    Time frame: 4 years

07

Results

Posted Dec 18, 2023
Limitations and caveats
The trial was early terminated after the end of its Phase 1 due to lack of funding. As a result it was not possible to analyse the objectives of the study.

Participant flow

A total of 15 patients were recruited in the Phase 1 part of the study in 5 centers across 4 countries (Luxembourg, Israel, Spain and USA). The study was early terminated prior starting the Phase 2 due to lack of fundings. The following number of treated patients were initially planned to be recruited: up to 30 in the Phase 1 and 100 in the Phase 2.

Participant flow — Overall Study
MilestoneDose Level 1Dose Level 2Dose Level 3
Started663
Completed000
Not completed663
Withdrew: Death001
Withdrew: Withdrawal by subject010
Withdrew: Physician decision001
Withdrew: Progression440
Withdrew: Clinical monitoring committee and physician choice111
Withdrew: Transfer to spring rollover protocol (eu ct # 2022-500041-24-00) after closing spring100

Outcome measures

PrimaryIncidence of the Tested 3-Drug Combination Therapy-Emergent Adverse Events and Serious Adverse Events

The occurrence of adverse events and serious adverse events reported from the signing of an informed consent through 90 days after the last administration of the treatment will be summarized for all subjects who received at least one dose of the study treatment (safety population) and will be evaluated based on NCI CTCAE v4.03: June 14, 2010.

Time frame:
From informed consent signature through 90 days after administration of the treatment (last dose)

No measurements were reported for this outcome.

PrimaryResponse Rate (RR)

Response rate is defined as the proportion of participants with reduction in tumor burden of a predefined amount based on RECIST 1.1 evaluation

Time frame:
Baseline up to approximately 24 months

No measurements were reported for this outcome.

PrimaryDuration of the Response

Duration of Response (DR) is defined for patients with confirmed objective response (Complete Response \[CR\] or Partial Response \[PR\]) as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.

Time frame:
Baseline up to approximately 24 months

No measurements were reported for this outcome.

PrimaryProgression-Free Survival (PFS)

Progression Free Survival (PFS) is defined as the time from the first dose of study treatment to the date of disease progression by RECIST 1.1 or death due to any cause, whichever occurs first.

Time frame:
Baseline up to approximately 24 months

No measurements were reported for this outcome.

PrimaryOverall Survival (OS)

OS is defined as the time from the first dose of study treatment to the date of death due to any cause.

Time frame:
Baseline up to approximately 24 months

No measurements were reported for this outcome.

PrimarySIMS Algorithm to Predict Clinical Outcome

The proportion of participants whose SIMS analysis matches the treatment combination, will be correlated retrospectively to clinical outcome.

Time frame:
4 years

No measurements were reported for this outcome.

SecondaryIncidence of Treatment-related and or Biopsy-related Serious Adverse Events

The occurrence of treatment-related and or biopsy-related serious adverse events as assessed by NCI CTCAE v4.03 will be summarized for all study subjects.

Time frame:
4 years

No measurements were reported for this outcome.

SecondaryGenomic and Transcriptomic Profile

Genomic (DNA) and transcriptomic (RNA) aberrations (mutations, translocations, rearrangements and changes in expression level) identified in the study population (Non-Small Cell Lung) will be described.

Time frame:
4 years

No measurements were reported for this outcome.

Adverse events

Collected over From the time of Informed Consent through the follow-up period of 90 days after discontinuation of the study treatment, up to 4,5 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level 12/6 (33.3%)3/6 (50%)6/6 (100%)
Dose Level 21/6 (16.7%)4/6 (66.7%)6/6 (100%)
Dose Level 31/3 (33.3%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventDose Level 1Dose Level 2Dose Level 3
Infusion related reactionGeneral disorders0/62/60/3
Neutrophil count decreasedInvestigations0/60/61/3
Respiratory failureRespiratory, thoracic and mediastinal disorders0/60/61/3
AnaemiaBlood and lymphatic system disorders0/61/60/3
Coronary artery diseaseCardiac disorders1/60/60/3
Disease progressionGeneral disorders1/61/60/3
FatigueGeneral disorders0/61/60/3
General physical health deteriorationGeneral disorders1/60/60/3
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/60/60/3
EpistaxisRespiratory, thoracic and mediastinal disorders0/61/60/3
Most frequent other events
Showing 10 of 151
Most frequent other events
EventDose Level 1Dose Level 2Dose Level 3
DyspnoeaRespiratory, thoracic and mediastinal disorders3/61/63/3
HypertensionVascular disorders3/64/63/3
Activated partial thromboplastin time prolongedInvestigations5/60/60/3
ProteinuriaRenal and urinary disorders5/62/61/3
FatigueGeneral disorders4/63/61/3
PainGeneral disorders4/60/60/3
Neutrophil count decreasedInvestigations4/63/60/3
Platelet count decreasedInvestigations3/64/60/3
Weight decreasedInvestigations4/62/61/3
White blood cell count decreasedInvestigations4/63/60/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Dose Level 1Dose Level 2Dose Level 3Total
<=18 years0000
Between 18 and 65 years3227
>=65 years3418
Age, Continuous
Age, Continuous(years)Dose Level 1Dose Level 2Dose Level 3Total
Median68 (52 to 80)67 (51 to 72)54 (51 to 76)67 (51 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1Dose Level 2Dose Level 3Total
Female3115
Male35210
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Level 1Dose Level 2Dose Level 3Total
Caucasian66214
Mexican0011
Black0000
Asian0000
Region of Enrollment
Region of Enrollment(participants)Dose Level 1Dose Level 2Dose Level 3Total
United States5027
Luxembourg0202
Israel0213
Spain1203
08

Study locations

5 sites
  • UCSD Moores Cancer Center
    La Jolla, California 92093, United States
  • Avera Cancer Center
    Sioux Falls, South Dakota 57105, United States
  • Chaim Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • Centre Hospitalier Luxembourg
    Luxembourg, 1210, Luxembourg
  • Vall Hebron Institute of Oncology
    Barcelona, 08035, Spain
09

References and documents

Publications

  • Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, Wunder F, Raynaud J, Girard N, Lee JJ, Sulaiman R, Prouse B, Bresson C, Ventura H, Magidi S, Rubin E, Young B, Onn A, Leyland-Jones B, Schilsky RL, Lazar V, Felip E, Kurzrock R. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. 2022 Jul;11(14):2790-2800. doi: 10.1002/cam4.4635. Epub 2022 Mar 20. PubMed 35307972 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Dec 2022, 61 months.

Results were first posted in Dec 2023, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2017
First posted
Dec 29, 2017
StartActual
Nov 29, 2017
Primary completionActual
Dec 29, 2022
CompletionActual
Dec 29, 2022
Results first posted
Dec 18, 2023
Last update
Dec 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03386929
Lead sponsor
Worldwide Innovative Network Association
Collaborators
ARC Foundation for Cancer Research, Pfizer
Responsible party
Sponsor
First posted
Dec 29, 2017
Start date
Nov 29, 2017
Primary completion
Dec 29, 2022
Completion
Dec 29, 2022
Results posted
Dec 18, 2023
Last update
Dec 18, 2023

Study contacts

RAZELLE KURZROCK, MD
principal investigator · Medical College of Wisconsin, Milwaukee, WI, USA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Avelumab · Axitinib · Palbociclib

Start the discussion